Manish Raturi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Manish Raturi has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Yashaswi Dhiman
Department of Immunohematology and Blood Transfusion, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India
15 shared publicationsAnuradha Kusum
Department of Pathology Himalayan Institute of Medical Sciences Dehradun IND
10 shared publications- Shamee Shastry
Department of Immunohematology and Blood Transfusion, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India
10 shared publications Mansi Kala
Swami Rama Himalayan Univ, Himalayan Inst Med Sci, Dept Pathol, Dehra Dun, Uttarakhand, India
9 shared publicationsA. Kusum
Swami Rama Himalayan Univ, Himalayan Inst Med Sci, Dept Pathol, Dehra Dun 248016, Uttarakhand, India
7 shared publicationsDushyant Singh Gaur
Department of Immunohematology and Blood Transfusion, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Swami Ram Nagar, Jolly Grant Dehradun-248016 Uttarakhand, India
7 shared publications
Latest Publications
- 11 July 2026
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 33 (4) , 302-303
Integrating laboratory-verified ABO and RhD blood group information into India's Aadhaar card: A public health perspective
- 11 July 2026
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 33 (4) , 302-303
Integrating laboratory-verified ABO and RhD blood group information into India's Aadhaar card: A public health perspective
- Open Access
- 9 January 2026
- Published by Springer Nature in Cureus
- Vol. 18 (1)
Serological and Clinical Evaluation of Incompatible Crossmatches Encountered in Pre-transfusion Testing
Background Pre-transfusion testing is essential for preventing incompatible red cell transfusions and associated adverse reactions. Despite modern serological advancements, unexpected alloantibodies, autoantibodies, and monoclonal antibody interference continue to contribute to incompatible crossmatches. This study evaluates the serological patterns, clinical associations, and diagnostic considerations of incompatible crossmatches encountered in routine transfusion practice. Methods This cross-sectional study was conducted at a tertiary-care transfusion service of Swami Rama Himalayan University, Dehradun, India, over a duration of 18 months, from April 2023 to September 2024. Of 34,631 packed red blood cell (PRBC) crossmatches performed, 46 (0.13%) showing major incompatibility were included. Detailed clinical history, hematological parameters, and immunohematological testing, including Direct Coombs Test (DCT), Indirect Coombs Test (ICT), extended antibody panels, and daratumumab interference assessment, were performed. Associations between antibody category and clinical variables were analyzed using Chi-square/Fisher’s exact tests, with p < 0.05 considered significant. Results Among 46 incompatible crossmatches, alloantibodies were the most frequent antibody type (24; 52.1%), followed by autoantibodies (16; 34.8%) and daratumumab interference (6; 13.0%). DCT status showed a significant association with antibody type (p = 0.001), with autoantibodies observed exclusively in DCT-positive cases (16/16; 100%), while daratumumab interference occurred only in DCT-negative cases (6/6; 100%). Significant associations were observed for age group (p = 0.012), clinical diagnosis (p = 0.001), previous transfusion history (p = 0.001), number of PRBC units transfused (p = 0.001), hepatomegaly (p = 0.009), and splenomegaly (p = 0.001). Younger patients predominantly exhibited alloantibodies, whereas patients older than 50 years showed contributions from all antibody categories. Autoantibodies predominated in benign hematological disorders (12; 75.0%), while daratumumab interference was confined to hematological malignancies (6; 100%). Gender (p = 0.463) and Rh typing (p = 0.076) were not significantly associated with antibody distribution. Logistic regression analysis did not identify reliable independent predictors due to wide confidence intervals and model instability. Conclusion Most incompatible crossmatches were caused by alloantibodies, though clinically significant contributions from autoantibodies and daratumumab interference were also observed. Strong associations with demographic and diagnostic variables highlight the importance of individualized immunohematological assessment. Routine use of structured diagnostic algorithms can enhance resolution of incompatible crossmatches and strengthen transfusion safety.
- 9 January 2026
- Published by Springer Nature in Cureus
- Vol. 18 (1)
Open AccessSerological and Clinical Evaluation of Incompatible Crossmatches Encountered in Pre-transfusion Testing
Background Pre-transfusion testing is essential for preventing incompatible red cell transfusions and associated adverse reactions. Despite modern serological advancements, unexpected alloantibodies, autoantibodies, and monoclonal antibody interference continue to contribute to incompatible crossmatches. This study evaluates the serological patterns, clinical associations, and diagnostic considerations of incompatible crossmatches encountered in routine transfusion practice. Methods This cross-sectional study was conducted at a tertiary-care transfusion service of Swami Rama Himalayan University, Dehradun, India, over a duration of 18 months, from April 2023 to September 2024. Of 34,631 packed red blood cell (PRBC) crossmatches performed, 46 (0.13%) showing major incompatibility were included. Detailed clinical history, hematological parameters, and immunohematological testing, including Direct Coombs Test (DCT), Indirect Coombs Test (ICT), extended antibody panels, and daratumumab interference assessment, were performed. Associations between antibody category and clinical variables were analyzed using Chi-square/Fisher’s exact tests, with p < 0.05 considered significant. Results Among 46 incompatible crossmatches, alloantibodies were the most frequent antibody type (24; 52.1%), followed by autoantibodies (16; 34.8%) and daratumumab interference (6; 13.0%). DCT status showed a significant association with antibody type (p = 0.001), with autoantibodies observed exclusively in DCT-positive cases (16/16; 100%), while daratumumab interference occurred only in DCT-negative cases (6/6; 100%). Significant associations were observed for age group (p = 0.012), clinical diagnosis (p = 0.001), previous transfusion history (p = 0.001), number of PRBC units transfused (p = 0.001), hepatomegaly (p = 0.009), and splenomegaly (p = 0.001). Younger patients predominantly exhibited alloantibodies, whereas patients older than 50 years showed contributions from all antibody categories. Autoantibodies predominated in benign hematological disorders (12; 75.0%), while daratumumab interference was confined to hematological malignancies (6; 100%). Gender (p = 0.463) and Rh typing (p = 0.076) were not significantly associated with antibody distribution. Logistic regression analysis did not identify reliable independent predictors due to wide confidence intervals and model instability. Conclusion Most incompatible crossmatches were caused by alloantibodies, though clinically significant contributions from autoantibodies and daratumumab interference were also observed. Strong associations with demographic and diagnostic variables highlight the importance of individualized immunohematological assessment. Routine use of structured diagnostic algorithms can enhance resolution of incompatible crossmatches and strengthen transfusion safety.
- 22 December 2025
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 33 (1) , 64
The Crimson Laureate’s vision: Establishing a Paw Blood Bank for all creatures great and small
- 22 December 2025
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 33 (1) , 64
The Crimson Laureate’s vision: Establishing a Paw Blood Bank for all creatures great and small
- 29 July 2025
- Published by Elsevier in Current Opinion in Immunology
- Vol. 96, 102617
Immunological complications of blood transfusion: current insights and advances
- 29 July 2025
- Published by Elsevier in Current Opinion in Immunology
- Vol. 96, 102617
Immunological complications of blood transfusion: current insights and advances
- 29 April 2025
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 32 (3) , 325
Fragile beginnings enduring legacy: the blood bag story
- 29 April 2025
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 32 (3) , 325
Fragile beginnings enduring legacy: the blood bag story
- 11 January 2025
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 32 (1) , 128
The tireless journey of the resilient little red blood cell
- 11 January 2025
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 32 (1) , 128
The tireless journey of the resilient little red blood cell
- 20 December 2024
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 32 (1) , 118-120
Blood group misinformation impacting the attendant’s decision-making for a timely blood transfusion to their patient: An ethical dilemma
- 20 December 2024
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 32 (1) , 118-120
Blood group misinformation impacting the attendant’s decision-making for a timely blood transfusion to their patient: An ethical dilemma